Pancreatic cancer–associated stroma production
Section snippets
Molecular Aspects of Pancreatic Cancer
PDAC is known to overexpress many mitogenic growth factors and their corresponding high-affinity tyrosine kinase receptors [7], and to harbor a high frequency of mutations in the K-ras oncogene, the p53 and Smad4 tumor-suppressor genes, and the p16 cell cycle inhibitory gene [8]. In addition, there is excessive activation of downstream signaling pathways, such as the src, nuclear factor κB (NFκB), and Stat3 signaling pathways [9], [10], [11]. Together, these alterations enhance cancer cell
Origin of Pancreatic Cancer and Its Associated Stroma
The exact cell type that gives rise to PDAC is not known. In theory, PDAC may arise from a poorly differentiated ductal cell, a de-differentiated acinar or islet cell, a progenitor cell, or a stem cell. In recent years there has been a growing appreciation that pancreatic intraepithelial neoplasias (PanINs) constitute precancerous lesions that lead to PDAC [12], [13]. Low-grade lesions are termed PanIN-IA and PanIN-1B, and these lesions often harbor activating K-ras mutations.
Potential Role of Stroma in Pancreatic Cancer: Invasion and Metastasis
Several types of tumor–stroma interactions have been implicated as having the potential to promote pancreatic cancer cell invasion and metastasis. Cancer cell–derived growth factors, such as fibroblast growth factors (FGFs), transforming growth factor–β (TGF-βs), insulin-like growth factor-1 (IGF-1), and platelet-derived growth factor BB (PDGF-BB), become sequestered within the stroma, which thus acts as a storage site for these factors. The invading cancer cells produce matrix
Stroma-Targeted Therapeutics
The conclusion that the stroma and aberrant stromal–epithelial interactions contribute to pancreatic cancer spread and metastasis raises the possibility that targeting the stroma may represent an additional approach for treating pancreatic cancer. In this regard, any agents that target pro-fibrotic growth factors, such as small molecule tyrosine kinase inhibitors that interfere with epidermal growth factor (EGF) receptor, FGF receptor, PDGF receptor, or IGF-1 receptor signaling, may be useful
References (34)
- et al.
AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinomaAmerican Gastroenterological Association
Gastroenterology
(1999) - et al.
Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database
J Am Coll Surg
(1999) - et al.
Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis
Gastroenterology
(2002) - et al.
Identification of an autoregulatory feedback pathway involving interleukin-1alpha in induction of constitutive NF-kappaB activation in pancreatic cancer cells
J Biol Chem
(2004) - et al.
Genetic progression in the pancreatic ducts
Am J Pathol
(2000) - et al.
Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice
Cancer Cell
(2005) - et al.
Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells
Gastroenterology
(2005) - et al.
Enhanced expression of transforming growth factor-beta isoforms in human pancreatic cancer correlates with decreased survival
Gastroenterology
(1993) Cancer of the pancreas: 50 years of surgery
Cancer
(1987)- et al.
Pancreatic carcinoma
N Engl J Med
(1992)
Chemosensitivity testing and test-directed chemotherapy in human pancreatic cancer
Recent Results Cancer Res
Pancreatic cancer: an agenda for action
Report of the Pancreatic Cancer Progress Review Group
Biology of pancreatic cancer
Molecular pathogenesis of pancreatic cancer
Annu Rev Genomics Hum Genet
c-Src regulates constitutive and EGF-mediated VEGF expression in pancreatic tumor cells through activation of phosphatidyl inositol-3 kinase and p38 MAPK
Pancreas
Genetics and biology of pancreatic ductal adenocarcinoma
Genes Dev
Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations
Cancer Res
Cited by (0)
Supported by a grant from the National Cancer Institute (CA-75059).